Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to describe the pharmacokinetics (PK) of six different dosing
regimens of epoetin alfa (PROCRIT®) in anemic critically ill subjects
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.